Compare Adaptive Biotechnologies Corp (ADPT) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Trade Desk Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Trade Desk Inc trades at $13.46 (market cap $6.37B). The key difference: Trade Desk Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | TTD | |
|---|---|---|
Market Cap | $4.04B | $6.37B |
Sector | Health | Technology |
52-Week High | $25.45 | $55.36 |
52-Week Low | $12.30 | $13.39 |
Enterprise Value | $4.10B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
The Trade Desk (TTD) trades at $13.66, down 90% from its 2024 peak, with bearish technical signals and recent earnings misses. Revenue growth slowed to 3% in Q2 2026, and Q3 guidance projects a 12% decline. Despite strong profitability margins (net margin 13.6%), the stock faces execution challenges and advertiser pressure. Analyst sentiment is mixed with a $13.87 price target, while institutional selling and downgrades reflect mounting concerns.
Outlook remains cautious amid weak guidance and competitive threats, though current valuations (P/E 16.1) may attract value investors. Key risks include persistent revenue declines and market share erosion. Recovery hinges on stabilizing advertiser relationships and reversing recent execution gaps.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
